Review about Naltrexone

This page shows detailed information about a specific drug review.

Naltrexone

11/25/2020 | | 58moderated by Henry
Naltrexone (50MG) for Fibromyalgia (FM or FMS)

I tried naltrexone at a low dose of 4.5 mg dose years ago, and it had no effect on my pain levels. But at a higher dose (I started with 24.5 mg and now take 50 mg) it is extraordinarily effective. I'm thrilled with this result, but I worry about the long-term effects, so I do not plan to take it indefinitely. The side effects - energy, a spacey feeling - I find pleasant. But this also makes me worry that perhaps this is just another painkiller, and that I'll build up a tolerance and be worse off when I try to wean myself off it. It's promoted as safer and non-addictive, but not enough is known about it yet for those claims to be trusted. It perplexes me that naltrexone is an opioid antagonist, but it feels slightly like an opioid to me. So I'm trilled to have relief from the pain, but I proceed with caution.

0 reactions

Reactions to this review

No reactions found at this moment.

The list of reactions to this review is empty. Please check back later.

The content on this page is user-generated content, read and revised before approval to comply with our standards for a drug review or reaction. We do not enforce any proven medical knowledge from our users to allow them to present their experiences. This way, the opinions and experiences described state only the views of the writers and not those of the owner of this website. Remember that these experiences differ from person to person and that you should always contact your doctor or pharmacist for advice on medication.

Add your reaction to this review



IMPORTANT: this email address is from the person giving this reaction and will be kept private. It will only be used by us to contact you about your reaction or if you check the option below.

Copyright © 2008-2021 Insight Pharma Services BV.
All rights reserved.
Icons made by Prosymbols from www.flaticon.com and licensed as CC 3.0 BY.